MERIT’s latest white paper is now available! FAF-measured lesion area has anchored GA trial design for nearly two decades, and it got us to the first approved therapies. However, it has known limitations: no depth resolution, limited sensitivity in earlier disease stages, and functional outcomes that haven’t always tracked with anatomic slowing. In this new white paper, Dr. Ronald Danis, MERIT’s CSO, examines how OCT-based structural endpoints, including ellipsoid zone attenuation, choroidal hypertransmission defects, and MERIT’s outer retina-choroid (ORC™) imaging approach, are reshaping endpoint strategy for dry AMD trials.
Download it here. Free and ungated for a limited time, released in conjunction with AAO 2026.